Form 4: Dyne Therapeutics Director Dirk Kersten Sells Shares Under 10b5-1 Trading Plan

Director Dirk Kersten reports the sale of Dyne Therapeutics (DYN) shares held by Forbion Capital Fund IV Cooperatief U.A. under a pre-arranged 10b5-1 trading plan.

Summary

• Dirk Kersten, a director at Dyne Therapeutics, reported the sale of common stock on August 26 and 27, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• On August 26, 2024, 77,963 shares were sold at a weighted average price of $45.23, with prices ranging from $44.71 to $45.70.
• An additional 11,534 shares were sold on August 26, 2024, at a weighted average price of $45.79, with prices ranging from $45.71 to $46.16.
• On August 27, 2024, 65,403 shares were sold at a weighted average price of $44.28, with prices ranging from $43.79 to $44.67.
• After these transactions, FCF IV directly holds 642,498 shares, and ForDyne B.V. holds 5,795,364 shares.
• The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Negatives

• A director selling shares could be perceived negatively by some investors.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes create uncertainty in the market.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Insider transactions are common in the biopharmaceutical industry. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• It's common for directors at publicly traded companies, especially in the biotech sector, to utilize 10b5-1 trading plans to diversify their holdings or manage personal finances.
• The volume of shares sold is relatively small compared to the total outstanding shares of Dyne Therapeutics.
• Comparable companies such as Sarepta Therapeutics or BioMarin Pharmaceutical also see regular insider trading activity.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment in the short term.

Key Dates